首页> 外文期刊>Advances in Medical Education and Practice >A call to maximize impact of the SUPPORT for Patients and Communities Act through standard inclusion of opioid use disorder treatment curricula in medical schools
【24h】

A call to maximize impact of the SUPPORT for Patients and Communities Act through standard inclusion of opioid use disorder treatment curricula in medical schools

机译:通过在医学院校标准纳入阿片类药物使用障碍治疗课程,呼吁最大限度地提高《支持患者和社区法》的影响

获取原文
           

摘要

Physicians who want to prescribe buprenorphine to treat opioid use disorder require a waiver established by the Drug Addiction Treatment Act (DATA) of 2000, often through completion of an eight-hour training course. This is an issue for a number of reasons, including that opioid overdose deaths continue to rise nationally. However, on October 24, 2018, the SUPPORT (Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment) for Patients and Communities Act was signed into law. This bill allows any physician who graduates in good standing from an allopathic or osteopathic medical school in the United States that incorporates necessary material around opioid misuse in their standard curriculum, without need for any additional training, to prescribe buprenorphine. This perspective piece describes why this is an important first step and what more needs to be done within medical education to combat the opioid epidemic.
机译:想要开处方丁丙诺啡以治疗阿片类药物使用失调的医生,通常需要通过八小时的培训课程来获得2000年《药物成瘾治疗法》(DATA)规定的豁免。由于许多原因,这是一个问题,包括阿片类药物过量死亡在全国范围内继续上升。但是,2018年10月24日,《患者和社区支持法》(促进阿片类药物恢复和治疗的物质使用失调预防)签署成为法律。该法案允许任何在美国的同种异体疗法或整骨疗法医学院毕业且信誉良好的医师开处方丁丙诺啡,而该医师将关于阿片类药物滥用的必要材料纳入其标准课程,而无需任何额外的培训。该观点文章描述了为什么这是重要的第一步,以及在医学教育中还需要做更多的工作来对抗阿片类药物的流行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号